TY - CHAP A1 - Stöllner, Thomas A1 - Breitenlechner, Elisabeth A1 - Eibner, Clemens A1 - Herd, Rainer A1 - Kienlin, Tobias A1 - Lutz, Joachim A1 - Maass, Alexander A1 - Nicolussi, Kurt A1 - Pichler, Thomas A1 - Pils, Robert A1 - Röttger, Klaus A1 - Song, Baoquan A1 - Taube, Nadine A1 - Thomas, Peter A1 - Thurner, Andrea ED - Goldenberg, Gert ED - Töchterle, Ulrike ED - Oeggl, Klaus ED - Krenn-Leeb, Alexandra T1 - Der Mitterberg - der Großproduzent für Kupfer im östlichen Alpenraum während der Bronzezeit T2 - Forschungsprogramm HiMAT - Neues zur Bergbaugeschichte der Ostalpen KW - Mitterberg Y1 - 2011 SN - 978-3-902572-03-5 SP - 113 EP - 144 PB - Österreichische Gesellschaft für Ur- und Frühgeschichte CY - Wien ER - TY - GEN A1 - Kammerer, Sarah A1 - Jahn, Stephan Wenzel A1 - Winter, Elke A1 - Eidenhammer, Sylvia A1 - Rezania, Simin A1 - Regitnig, Peter A1 - Pichler, Martin A1 - Schreibmayer, Wolfgang A1 - Bauernhofer, Thomas T1 - Critical evaluation of KCNJ3 gene product detection in human breast cancer: MRNA in situ hybridisation is superior to immunohistochemistry T2 - Journal of Clinical Pathology N2 - Increased expression levels of KCNJ3 have been correlated with lymph node metastases and poor prognosis in patients with breast cancer, suggesting a prognostic role of KCNJ3. We aimed to establish protocols for the detection of KCNJ3 in formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue. Several antibodies were tested for sensitivity and specificity by western blot, followed by optimisation of the immunohistochemistry (IHC) procedure and establishment of KCNJ3 mRNA in situ hybridisation (ISH). Methods were validated by processing 15 FFPE breast cancer samples for which microarray data were available. Spearman's rank correlation analysis resulted in borderline significant correlation for IHC versus ISH (rS: 0.625; p<0.05) and IHC versus microarray (rS: 0.668; p<0.01), but in significant correlation for ISH versus microarray (rS: 0.861; p<0.001). The ISH method was superior to IHC, regarding robustness, sensitivity and specificity and will aid to further study expression levels of KCNJ3 in both malignant and physiological conditions. Y1 - 2016 U6 - https://doi.org/10.1136/jclinpath-2016-203798 SN - 1472-4146 SN - 0021-9746 VL - 69 IS - 12 SP - 1116 EP - 1121 ER - TY - GEN A1 - Kammerer, Sarah A1 - Sokolowski, Armin Andreas A1 - Hackl, Hubert A1 - Platzer, Dieter A1 - Jahn, Stephan Wenzel A1 - El-Heliebi, Amin A1 - Schwarzenbacher, Daniela A1 - Stiegelbauer, Verena A1 - Pichler, Martin A1 - Rezania, Simin A1 - Fiegl, Heidelinde A1 - Peintinger, Florentia A1 - Regitnig, Peter A1 - Höfler, Gerald A1 - Schreibmayer, Wolfgang A1 - Bauernhofer, Thomas T1 - KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients T2 - OncoTarget : open access impact journal N2 - Numerous studies showed abnormal expression of ion channels in different cancer types. Amongst these, the potassium channel gene KCNJ3 (encoding for GIRK1 proteins) has been reported to be upregulated in tumors of patients with breast cancer and to correlate with positive lymph node status. We aimed to study KCNJ3 levels in different breast cancer subtypes using gene expression data from the TCGA, to validate our findings using RNA in situ hybridization in a validation cohort (GEO ID GSE17705), and to study the prognostic value of KCNJ3using survival analysis. In a total of > 1000 breast cancer patients of two independent data sets we showed a) that KCNJ3 expression is upregulated in tumor tissue compared to corresponding normal tissue (p < 0.001), b) that KCNJ3 expression is associated with estrogen receptor (ER) positive tumors (p < 0.001), but that KCNJ3 expression is variable within this group, and c) that ER positive patients with high KCNJ3 levels have worse overall (p < 0.05) and disease free survival probabilities (p < 0.01), whereby KCNJ3 is an independent prognostic factor (p <0.05). In conclusion, our data suggest that patients with ER positive breast cancer might be stratified into high risk and low risk groups based on the KCNJ3 levels in the tumor. Y1 - 2016 U6 - https://doi.org/10.18632/oncotarget.13224 VL - 7 IS - 51 SP - 84705 EP - 84717 ER -